Fig. 3: Synergistic effects of combinatorial therapy with DHA and docetaxel in vivo.
From: Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
DU145shGFP cells (5 × 106) were implanted subcutaneously into the right flank of MF-1 mice. Mice were randomly divided into 4 groups (n = 6/group): Mice submitted to treatment with DMSO (2 mL/kg/daily), DHA (40 mg/kg/daily), docetaxel or combination of DHA (40 mg/kg/daily) and docetaxel (15 mg/kg/daily) as described in Material and methods. a Analysis of a tumor volume progression and b tumor volume. Values are represented as mean ± SD of six individuals; *p < 0.05 and **p < 0.001, two-tailed Student’s t-test. c Analysis of IL-6 levels in the blood of mice. Values are represented as mean ± SD of six individuals; * p < 0.05, two-tailed Student’s t-test. d Survival curve of mice treated DMSO (2 mL/kg/daily), DHA (40 mg/kg/daily), docetaxel (15 mg/kg/daily) or combination of DHA (2 mL/kg/daily) and docetaxel (15 mg/kg/daily)
